Novartis AG vs Occidental Petroleum Corporation — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Occidental Petroleum Corporation trades at $60.05 (market cap $58.19B). The key difference: Novartis AG is far larger — about 4.7× Occidental Petroleum Corporation's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Occidental Petroleum Corporation for 92 Days on average.
| NVS | OXY | |
|---|---|---|
Market Cap | $274.00B | $58.19B |
Volume | 1,852,137 | 7,092,290 |
Sector | Health | Energy |
52-Week High | $168.62 | $66.24 |
52-Week Low | $121.80 | $38.92 |
Typical Hold Time | 82 Days | 92 Days |
Enterprise Value | $315.32B | $76.95B |
Dividend Yield | 3.31% | 1.92% |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Occidental Petroleum (OXY) trades at $60.28, up 3.34% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by a consensus price target of $71.40, indicating potential upside. Recent news highlights Goldman Sachs' upgrade to Buy, citing cash flow targets and debt reduction. Revenue has declined from $36.6B in 2022 to $21.6B in 2025, but net income margin remains healthy at 30.32%, and the company maintains a solid balance sheet with manageable debt levels.
OXY presents a favorable risk-reward profile with analyst optimism and operational efficiency, though exposure to oil price volatility and competitive pressures pose risks. The upcoming Q3 2026 earnings report on November 9 is a key catalyst. Institutional sentiment is positive, with 52% of analysts rating it Buy. Investors should weigh the stock's valuation appeal against macroeconomic headwinds affecting the energy sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →